North America
Boston 5

Our Local Leaders

Terence Shepherd, CM&AA, CPA, MST Principal, Founding Member
Carl Goldstein
Carl Goldstein, CPA Principal, Founding Member
Joe Vajda
Joseph J Vajda, MBA Senior Consultant
Jenn Moore
Jenn Moore Business Transition Consultant

Recent Projects

One of the first things prospective buyers look at is the strength of your management team. Our hands-on mentoring program is designed from an extensive SWOT analysis customized to each business.

Terry Shepherd – Managing Partner of ROCG’s Boston office recently wrote an article that was published by the Cape Business Journal. To read more click here…

Prior Events March 15, 2013

Click here to view past events and feel free to contact if you want to book these topics for your next event or trade association conference

See all recent Boston news/projects

Local Events

There are no local events

Our Local News

'She-Village,' block of women-owned pop-up shops, opens in Seaport

A pop-up village opened Sunday in Boston's Seaport District, and its first installment is the “She-Village” — a block of nine pop-up shops from female-founded brands. The pop-up village, officially named The Current, will operate on a rotational basis, with new stores connected by a common theme coming in every six months. Its permanent location is 85 Northern Ave., next to District Hall and Seaport Common. Sunday is the village's soft opening, with a grand opening celebration planned…

Bike and scooter-sharing startups leave trail of questions in local cities

Startups from China and Silicon Valley are in a global war to get us all hooked on new forms of urban transportation, and local governments are starting to look like collateral damage. On Friday, city officials from Quincy, Cambridge and Somerville were all dealing with the fallout from unexpected moves by companies that rent out shared bikes and electric scooters to city residents for just a few dollars per ride. “We got caught up ... in a larger macro-economic situation,” said Chris Cassani,…

Cambridge's Agios wins FDA approval for second cancer drug

The FDA approved a cancer drug from Agios Pharmaceuticals Inc. on Friday after a Phase 1 clinical study found it aided a small group of patients suffering from a rare type of leukemia. Cambridge-based Agios (Nasdaq: AGIO) is developing treatments for several types of cancer, including acute myeloid meukemia, or AML. The rare blood and bone marrow disease worsens quickly and accounts for approximately one percent of cancer patients, according to the National Cancer Institute. Last year, Agios won…